Freedom: Alvotech’s $152M Follow-on Offering Sends Shares Down Nearly 9%, But May Support Long-Term Growth

Shares of biopharmaceutical company Alvotech declined 8.7% after announcing a $152 million capital raise through a secondary share offering. According to Freedom analyst Vladimir Chernov, the market’s negative reaction was expected, yet the deal could strengthen the company’s position in the long term.

Alvotech is an international biotechnology company specializing in the development and production of biosimilars — drugs that serve as more affordable versions of costly biological medicines. The company collaborates with major pharmaceutical players and is expanding its portfolio of drugs for the treatment of autoimmune, oncological, and other diseases.

The new shares were issued at $3.75 per share, representing an 11.6% discount to the previous closing price. As a result, the total number of the company’s outstanding shares will increase by nearly 13%, leading to dilution of existing shareholders’ stakes and putting downward pressure on the stock price.

In the short term, analysts expect continued elevated volatility near the offering level of $3.75 per share. However, for long-term investors, the current correction may present an opportunity to build a position. Accelerated commercialization of new drugs could improve Alvotech’s financial metrics and support its share price in the future.

Not an individual investment recommendation.